ACE2 and COVID-19: However, the available evidence, in particular from human studies, does not seem to support the hypothesis that inhibitors of ACE or renin-angiotensin–aldosterone (ACEI/ARB) drugs increase the ACE2 expression and the risk of COVID-19 [27].